Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FLI1
REST API REST API
Homo sapiens
FLI1 is differentially expressed in 313 experiments: 140 organism parts: lung, bone marrow, ... (138 more);, 274 disease states: normal, acute myeloid leukemia, ... (272 more);, 122 cell types 455 cell lines 39 compound treatments and 79 other conditions.
Synonyms SIC-1, EWSR2
Orthologs fli1a (Danio rerio)   E1BVB4_CHICK (Gallus gallus)   Fli1 (Mus musculus)   F6S5C8_CIOIN (Ciona intestinalis)   FLI1 (Bos taurus)   F6YFK6_CIOIN (Ciona intestinalis)   Q4H3K3_CIOIN (Ciona intestinalis)   Fli1 (Rattus norvegicus)   NP_001096189.1 (Xenopus laevis)   FLI1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, sequence-specific DNA binding, hemostasis, nucleus, organ morphogenesis, blood circulation, sequence-specific DNA binding transcription factor activity, RNA polymerase II distal enhancer sequence-specific DNA binding
InterPro Term Ets, Pointed_dom
UniProt Accession Q01543, B4DFV4, E9PKJ7
Gene-Disease Assocation EWING SARCOMA; ES
Search EB-eye ENSG00000151702
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-5823, E-GEOD-19639
HCC1954
2
E-MTAB-37, E-GEOD-29119
Jurkat
2
E-MTAB-62, E-GEOD-1880
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
HL-60
1
2
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
449 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (56 experiments)

Factor Value U/D Experiments
adipocyte
3
E-MTAB-25, E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
CD105+ endothelial
2
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-TABM-145, E-AFMX-5
116 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (71 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MEXP-231, E-MTAB-62
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20602
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
268 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
none
3
8
E-MEXP-1230, E-GEOD-5824, E-MEXP-1958, E-GEOD-2649, E-GEOD-412, ... (11 experiments)
lipopolysaccharide
1
2
E-GEOD-3720, E-MEXP-1958, E-TABM-868
vanadium pentoxide
1
E-GEOD-5339
galectin-1
1
E-GEOD-4984
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
TGF-Beta1
1
E-MEXP-2645
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-19665, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-TABM-127, E-GEOD-20540, E-GEOD-20504, E-GEOD-9764, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-1956, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, ... (9 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Processing time: 0.321 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM